Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Medicus Pharma Ltd. - Common Stock (NQ:MDCX)

0.2860 UNCHANGED

Streaming Delayed Price Updated: 4:00 PM EDT, May 21, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	16,480
Open	0.2860
Bid (Size)	0.2860 (500)
Ask (Size)	0.2877 (300)
Prev. Close	0.2860
Today's Range	0.2860 - 0.2860
52wk Range	0.2500 - 8.721
Shares Outstanding	N/A
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

New to The Street's Show #753 Airs Nationwide on Bloomberg Television Across the U.S., MENA and Latin America Featuring FreeCast (NASDAQ:CAST), Stardust Power (NASDAQ:SDST), Lost Soldier Oil and Gas, Virtuix Holdings (NASDAQ:VTIX), and Medicus Pharma

May 16, 2026

Via ACCESS Newswire

Medicus Pharma Reports First Quarter 2026 Financial Results and Provides Corporate Update

May 14, 2026

Company Advances SkinJect® and Teverelix® Clinical Programs While Strengthening Financing Flexibility and Expanding Strategic Development Initiatives

From Medicus Pharma Ltd

Via GlobeNewswire

Performance

YTD	-82.1%	-82.1%
1 Month	-12.7%	-12.7%
3 Month	-74.0%	-74.0%
6 Month	-86.0%	-86.0%
1 Year	-96.3%	-96.3%

More News

New to The Street Broadcasts Show #752 on Bloomberg Television Featuring Graphene Manufacturing Group (OTCQX:GMGRF), T-REX Acquisition Corp (NASDAQ:TRXA), KITON, and Roadzen (NASDAQ:RDZN)

May 09, 2026

Via ACCESS Newswire

Medicus Pharma Announces Results from Pre-Specified Expanded Phase 2 SKNJCT-003 Data Analysis Demonstrating Positive Dose-Response

May 06, 2026

From Medicus Pharma Ltd

Via GlobeNewswire

GLOBAL MARKETS SPOTLIGHT: New to The Street Show #748 Delivers High-Impact CEO Interviews and Spotlight TV Commercials Across Bloomberg to 250M+ Households Worldwide

May 01, 2026

Via ACCESS Newswire

Top movers in Monday's pre-market session ↗

April 27, 2026

Via Chartmill

Medicus Pharma CEO meets with lawmakers on Energy & Commerce Committee on Capitol Hill

April 27, 2026

From Medicus Pharma Ltd

Via GlobeNewswire

New to The Street Broadcasts Show #746 Tonight on Bloomberg Television 6:30PM EST Featuring NRx Pharma (NASDAQ:NRXP), Performance Golf, Lost Soldier Oil & Gas, Dr. Lee Gause, and CISO Global

April 25, 2026

Via ACCESS Newswire

New to The Street to Broadcast Tonight on Bloomberg at 6:30 PM EST - Show #744 Featuring Virtuix Holdings (NASDAQ:VTIX), Neonc Technologies Holdings (NASDAQ:NTHI), Medicus Pharma (NASDAQ:MDCX), YY Group Holding (NASDAQ:YYGH), and Vivos Therapeutics

April 18, 2026

Via ACCESS Newswire

Medicus Pharma Submits Orphan Drug Designation Application to U.S. FDA for SkinJect® in Gorlin Syndrome

April 17, 2026

From Medicus Pharma Ltd

Via GlobeNewswire

Medicus Pharma to Present New Teverelix Data at AACE 2026 Demonstrating Long-Acting Hormone Suppression

April 15, 2026

From Medicus Pharma Ltd

Via GlobeNewswire

New to The Street to Broadcast on Fox Business on Monday, April 13, Featuring Virtuix Holdings (NASDAQ:VTIX), Medicus Pharma (NASDAQ:MDCX), YY Group Holdings (NASDAQ:YYGH), Vivos Therapeutics (NASDAQ:VVOS), and Stardust Power (NASDAQ:SDST)

April 11, 2026

Via ACCESS Newswire

New to The Street Signs Medicus Pharma Ltd. (NASDAQ:MDCX) to Transformational 12-Part National Media Series Highlighting SkinJect(TM) and Teverelix(R) Platforms

April 07, 2026

Via ACCESS Newswire

Medicus Pharma Submits Optimized Phase 2 Study Protocol to U.S. FDA for Teverelix in Acute Urinary Retention

April 06, 2026

From Medicus Pharma Ltd

Via GlobeNewswire

Medicus Pharma Ltd Clarifies Positive SkinJect Phase 2 Dataset

April 01, 2026

From Medicus Pharma Ltd

Via GlobeNewswire

Medicus Pharma Reports KOL Validation of SkinJect Phase 2 Data of 80% Overall Response Rate

March 30, 2026

From Medicus Pharma Ltd

Via GlobeNewswire

Medicus Pharma (MDCX): A Small-Cap Biotech Making Moves in 2026

March 27, 2026

Via AB Newswire

Medicus Pharma Business Update Call to Highlight 80% Overall Response Rate (ORR) in Phase 2 SkinJect Study and Agentic AI-enabled Drug Development Plan

March 26, 2026

From Medicus Pharma Ltd

Via GlobeNewswire

Medicus Pharma Reports Full-Year 2025 Financial Results and Provides Corporate Update

March 25, 2026

Via ACCESS Newswire

Medicus Pharma To Discuss Positive Skinject(R) Phase 2 Topline Results In Fireside Chat Hosted By Brookline Capital Markets Biotechnology Equity Research Analyst

March 18, 2026

Via ACCESS Newswire

Medicus Pharma Announces SkinJect® Phase 2 Principal Investigator and Key Opinion Leader (KOL), Babar K. Rao MD, FAAD, to Provide Clinical Interpretation of Positive Data During Business Update Webcast on March 26

March 16, 2026

From Medicus Pharma Ltd

Via GlobeNewswire

New to The Street Episode #737 Airs on Bloomberg Television Across the United States, Latin America, and MENA at 6:30 PM EST

March 14, 2026

Via ACCESS Newswire

Unusual volume stocks in Tuesday's session ↗

March 10, 2026

Via Chartmill

Medicus Pharma Ltd. To Participate In The Longwood Miami CEO Forum

March 10, 2026

Via ACCESS Newswire

These stocks are making the most noise in today's session. ↗

March 09, 2026

Via Chartmill

Frequently Asked Questions

Is Medicus Pharma Ltd. - Common Stock publicly traded?

Yes, Medicus Pharma Ltd. - Common Stock is publicly traded.

What exchange does Medicus Pharma Ltd. - Common Stock trade on?

Medicus Pharma Ltd. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Medicus Pharma Ltd. - Common Stock?

The ticker symbol for Medicus Pharma Ltd. - Common Stock is MDCX on the Nasdaq Stock Market

What is the current price of Medicus Pharma Ltd. - Common Stock?

The current price of Medicus Pharma Ltd. - Common Stock is 0.2860

When was Medicus Pharma Ltd. - Common Stock last traded?

The last trade of Medicus Pharma Ltd. - Common Stock was at 05/21/26 04:00 PM ET

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.